What one share of ImageneBio holds
We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. Our lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (“OX40L”).
ImageneBio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.19 |
|---|---|
| Cash and investments | $11.99 |
| Book value | $12.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $66.49 | −$320.06 | $5.54 | −$279.10 | — | −$652.57 |
| 2021 | $22.15 | −$24.38 | $1.26 | −$44.32 | — | $115.57 |
| 2022 | $8.63 | −$38.00 | $0.79 | −$41.75 | — | $81.07 |
| 2023 | $4.39 | −$32.67 | $0.20 | −$38.41 | — | −$52.26 |
| 2024 | $1.45 | −$22.10 | — | — | — | −$66.54 |
| 2025 | $0.16 | −$9.64 | — | — | — | $27.33 |
Common questions about ImageneBio
How much does one share of ImageneBio earn?
Over the last 12 months, ImageneBio lost $5.19 for each share.
Does ImageneBio pay a dividend?
ImageneBio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is ImageneBio’s book value per share?
ImageneBio’s book value is $12.52 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of ImageneBio have?
Each share of ImageneBio has $11.99 of cash and investments, as of June 30, 2026.
Has ImageneBio bought back shares?
ImageneBio’s share count rose about 3423% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.